argenx SE ARGNF
Set alert
900.30 USD 0.00 0.00%
At close · Nov 2
995.00 Day range 995.00
712.03 52-week range 1,020.00
- YTD
- +3.48%
- 1 year
- +14.53%
- Open
- 995.00
- Prev close
- 900.30
- Mkt cap
- 56.62B
- Vol
- 49
- Avg vol
- 7
- EPS
- 28.87
- P/E
- 31.18
More statistics
- Low
- 995.00
- High
- 995.00
2Y chart
Events in this range
- May 8, 2025Earnings: 2.78; estimate —; surprise —%
- Oct 30, 2025Earnings: 7.33; estimate —; surprise —%
- May 7, 2026Earnings: 14.38; estimate —; surprise —%
Signals (52)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 29, 2026 | 5 days ago |
| MACD: Buy Signal | Oct 29, 2026 | 5 days ago |
| SMA: Bearish | Oct 13, 2026 | 3 weeks ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| RSI: Overbought | Aug 17, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 13, 2026 | 2 months ago |
| SMA: Bearish | Jul 17, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 10, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 25, 2026 | 4 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| RSI: Overbought | May 29, 2026 | 5 months ago |
| MACD: Sell Signal | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
| SMA: Bullish | May 5, 2026 | 6 months ago |
| MACD: Buy Signal | May 5, 2026 | 6 months ago |
| MACD: Sell Signal | May 1, 2026 | 6 months ago |
Newest 20 of 52.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 7, 2026 | Dec 31, 2025 | — | 14.38 | — | — |
| Oct 30, 2025 | Jun 30, 2025 | — | 7.33 | — | — |
| May 8, 2025 | Dec 31, 2024 | — | 2.78 | — | — |
| Oct 31, 2024 | Jun 30, 2024 | — | -0.51 | — | — |
| May 9, 2024 | Dec 31, 2023 | — | -3.01 | — | — |
News
- argenx: 3 Key Takeaways for Long-Term Investors
- Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
- BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
- Argenx to Buy Forte Biosciences for $2.2 Billion
- Argenx to buy Forte Biosciences for about $2.2 billion
- Argenx's Vyvgart sales jump in second quarter
- Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
- argenx SE (ARGX) Q1 2026 Earnings Call Transcript
Your note
Sign in to keep a note on ARGNF — it syncs with the Stock Master app.